Skip to content
City PM
  • Germany
  • France
  • Europe
  • Markets
  • Business
  • Opinion
  • Germany
  • France
  • Europe
  • Markets
  • Business
  • Opinion
Wednesday 25 August 2021 10:23 am  |  Updated:  Friday 12 November 2021 10:01 am

Covid protection from two vaccine doses fades after six months

By: Lily Russell-Jones

Add as a preferred source on Google
Vaccine doses delivered
Protection against Covid-19 from two vaccine doses starts to fade within six months according to UK researchers.

Protection against Covid offered by two doses of the Pfizer and the AstraZeneca vaccines begins to fade within six months underscoring the need for booster jabs according to UK researchers.

Scientists behind the Zoe Covid Study app said that effectiveness of the Pfizer vaccine against infection fell from 88 per cent to 74 per cent five to six months after the second jab.

Likewise, protection from the AstraZeneca vaccine decreased from 77 per cent to 67 per cent within four to five months of receiving the second dose.

Commenting on the study, Professor Finn of the University of Bristol, told the BBC: “I think the Zoe study, and a couple of other studies we recently had, do show the beginnings of a drop off of protection against asymptomatic or mildly symptomatic disease.

“But other studies are showing maintenance of good protection against serious illness and hospitalisation. So that’s encouraging actually that people who’ve had two doses are still very much well protected against serious illness, which is our main objective.”

The news comes after the government announced cautious plans to issue booster shots to the most vulnerable groups over the Winter to protect against Covid-19 and its future variants.

A study from the University’s of Glasgow and Birmingham recently found that 40 per cent of people who are immunosuppressed generated a lower antibody response with 11 per cent registering an “undetectable” amount of anti bodies within four weeks of being double jabbed.

Professor Finn, who is Chairman of the WHO’s European committee on immunisation, also said that the elderly would be good candidates for a third dose of the vaccine.

On Tuesday the government announced that a further 174 people had died within 28 days of testing positive for Covid-19, the highest reported daily death toll since March 12.

Read more: Third dose of Pfizer vaccine: Covid-19 booster shots ‘are working’

Read more

Alkermes Presents Detailed Positive Results From Vibrance-2 Phase 2 Study of Alixorexton in Adults With Narcolepsy Type 2 at SLEEP 2026

Share this article

  • Facebook
  • X
  • LinkedIn
  • WhatsApp
  • Email

Similarly tagged content:

Sections

  • News

Categories

  • Business

Related Topics

  • Coronavirus
  • Covid-19 a year on
  • Vaccine

Trending Articles

  • Top Burnham adviser calls for capital gains and inheritance tax hikes

  • Clarkson’s Farm and why businesses must stop blaming the weather

  • Two solicitors linked to Post Office scandal charged with misconduct

  • Lloyd’s deputy chair: The City is a club in the best sense

  • A meeting with the breakfast king of Mayfair

More from City PM

  • Alkermes Presents Detailed Positive Results From Vibrance-2 Phase 2 Study of Alixorexton in Adults With Narcolepsy Type 2 at SLEEP 2026

    Business Wire
  • Over Half of Consumers Will Pay More for Brands That Are Transparent About AI Data Use, New Usercentrics Research Finds

    Business Wire
  • Regulator wins decade-long pricing tussle with Pfizer

    Legal
    Hikma reported a jump in profit for 2024
  • Silence Therapeutics Highlights Follow-Up Data at EHA 2026 Demonstrating Durable Efficacy and Potential Best-in-Class Profile for Divesiran in Polycythemia Vera

    Business Wire
  • Assurant’s 2026 Global Connected Consumer Trends Report Finds That as Connected Tech Becomes More Critical, Reliability, Support, and Transparency Matter More Than Ever

    Business Wire
  • Alkermes to Present New Data on Alixorexton and LUMRYZ® (sodium oxybate) at SLEEP 2026, Highlighting Breadth of Sleep Medicine Research

    Business Wire
  • UK Companies Are Leaving Millions of Pounds Exposed and Underperforming

    Business Wire
  • LivaNova Demonstrates 84.5% Cumulative Response Rate with PolySync Programming in OSPREY Study for Obstructive Sleep Apnea

    Business Wire

City PM — European politics, business and analysis.

Europe

  • Germany
  • France
  • Europe
  • UK & Ireland

Topics

  • Business
  • Markets
  • AI
  • Technology
  • Opinion
  • Energy

More

  • Politics
  • Economics
  • Fintech
  • Legal
  • Sport
  • Life

Company

  • About City PM
  • Editorial Policy
  • Corrections
  • Contact
  • Terms of Use
  • Privacy Policy
  • Cookie Policy
© 2026 City PM · Published by CityPM Media, Bahnhofstrasse 65, 8001 Zürich, Switzerland
About · Editorial Policy · Corrections · Contact · Privacy